An Open-Label, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Proportion of patients with non-functioning pituitary adenomas (NFPA) who achieve tumor volume reduction of at least 20% after 24-week treatment with pasireotide LAR
24 weeks
Yes
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
Brazil: ANVISA (Angência Nacional Vigilãncia Sanitária)
CSOM230D2401
NCT01283542
November 2012
November 2014
Name | Location |
---|